Previous studies indicated that IL6R p.Asp358Ala [a commonly occurring variant in the IL-6 receptor (IL-6R) gene] could disrupt IL-6 signaling and provide a genetic proxy for tocilizumab, which reduces the risk of cardiovascular diseases in CHIP carriers [3, 4]. The gene discussed is STUB1; the disease is cardiovascular disorder.